Real-time tumor-tracking radiotherapy for adrenal tumors

Katoh, Norio; Onimaru, Rikiya; Sakuhara, Yusuke; Abo, Daisuke; Shimizu, Satoru; Taguchi, Hiroshi; Watanabe, Yoshiaki; Shinohara, Nobuo; Ishikawa, Masayori; Shirato, Hiroki

doi:10.1016/j.radonc.2008.03.013

Cited by 69 publications

(57 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Katoh et al 23 investigated three-dimensional tumour motion of the fiducial marker inserted in the adrenal metastasis resulting in a large marker shift related to organ movement, greater in the craniocaudal direction (1 cm). There was no statistically significant difference in the average amplitude between the supine and prone positions along the three axes, as well as with regard to the distance between the stomach, the duodenum and the tumour.…”

Section: Technical Issuesmentioning

confidence: 99%

SBRT: A viable option for treating adrenal gland metastases

Ippolito

D’Angelillo

Fiore

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tThe management strategy of adrenal metastases depends on different clinical situations.Adrenal metastasectomy in selected patients with isolated adrenal metastases is considered the treatment of choice, showing prolonged survival compared to chemotherapy alone.More recently, Stereotactic Body Radiation Therapy (SBRT) has emerged as an alternative local ablative treatment modality although limited data are available on the use of SBRT in treating adrenal gland metastases. Preliminary results are, however, encouraging, especially in selected patients with oligometastatic disease. We herewith review and discuss the potential role of SBRT as a local ablative treatment modality for adrenal metastases.

show abstract

Section: Technical Issuesmentioning

confidence: 99%

SBRT: A viable option for treating adrenal gland metastases

Ippolito

D’Angelillo

Fiore

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…39 There were also no differences in the minimum distances of implanted fiducial markers to the stomach or duodenum. As such, the supine position became standard as it is more comfortable for the patient.…”

Section: Simulationmentioning

confidence: 88%

“…As such, the supine position became standard as it is more comfortable for the patient. 39 All patients in modern series had 4D CT simulation scans to enable visualization of the maximum movement of the lesion in relation to normal structures. 37 Oral and intravenous contrast were often employed.…”

Section: Simulationmentioning

confidence: 99%

See 1 more Smart Citation

Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach?

Thomsen¹,

Fairchild²

2017

Oncology &Amp; Hematology Review (US)

View full text Add to dashboard Cite

B ackground: Five-year overall survival (OS) for patients with stage IV non-small cell lung cancer (NSCLC) is a dismal 1%. However, approximately 7% have limited or solitary metastases, including to the adrenal gland. Radical treatment of these oligometastases (OM) could increase local control and improve OS. Our objective was to critically analyze data describing aggressive treatment of adrenal OM secondary to NSCLC. Methods: A literature search examining English publications describing surgery or radiotherapy (RT) was performed, supplemented by searching reference lists. Case reports of three or fewer patients, and articles from which NSCLC-or adrenal-specific clinical outcomes could not be abstracted, were excluded. Results: Twenty-nine studies met eligibility criteria (521 patients), 26 retrospective. No publications directly compare modalities. Four surgery studies described contemporaneous patients treated with palliative chemotherapy (CH) alone. Reported median OS ranged from 9.5-64 months after adrenalectomy, 8-23 months after RT, and 6-8.5 months after CH. Local failure after surgery was 14%, with response rates after RT 57-75%. Both appear well-tolerated. Conclusions: In patients with an adrenal OM secondary to NSCLC, aggressive treatment should be considered. However, due to the paucity of high quality evidence, it is unclear at present whether this approach alters the natural history of the disease.

show abstract

“…Hastalara ortalama 50 Gy doz verilmiş olup, %73 hastada parsiyel yanıt elde edilmiş ve median sağkalım 10 ay bulunmuştur. [19] Katoh ve ark.nın [20] yaptıkları bir çalışmada fiducial işa-retleyici kullanılarak SBRT uygulanan 10 hastaya sekiz fraksiyonda 48 Gy doz uygulanmıştır. Hastalarda bir yıllık sağkalım %78, lokal kontrol %100 bulunmuştur.…”

Section: Hastalar Ve Yöntemunclassified